Jul. 14 at 4:24 PM
UBS reiterated
$PTCT Buy-
$71 after they hosted a medical geneticist and professor of pediatrics who is an expert on PKU and treats~320 patients.
$BMRN $SRPT $JNJ $BIIB NVS RHHBY LRMR RARE VRTX EWTX CAPR #KOL
UBS added, "Our discussion focused on the treatment paradigm in PKU with current management options (low-Phe diet, Kuvan/sapropterin, Palnynziq) as well as
$PTCT's sepiapterin (recently approved in Europe as Sephience, US FDA PDUFA 7/29).
Overall, we think the call was highly supportive of a strong potential launch for
$PTCT's sepiapterin.
UBS went on to give Their Key Takeaways from the Expert Call (In IMAGE Below):
